Consensus Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
25.94 USD +1.89% Intraday chart for Beam Therapeutics Inc. -3.50% -4.70%

Evolution of the average Target Price on Beam Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

c6a724fc093c.C_q7AX45ACqWxoNK1ivZyh9vnZvaWIvigWUCyD67GwA.Op79YiwUbl7Zn9shuHuym2dcr8uidemp6wJVvAmWVVJvzO1UFHtOGNnr4A~b7bb6e10b46f8c3621bf4edef32870d5
RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk MT
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing MT
Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38 MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35 MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75 MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61 MT
Citigroup Initiates Beam Therapeutics at Buy Rating With $62 Price Target MT
Credit Suisse Lowers Beam Therapeutics' Price Target to $53 From $65 to Reflect Delays to BEAM-102, Keeps Neutral Rating MT
Wedbush Adjusts Beam Therapeutics Price Target to $79 From $100, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
25.46 USD
Average target price
47.77 USD
Spread / Average Target
+87.62%
High Price Target
78 USD
Spread / Highest target
+206.36%
Low Price Target
23 USD
Spread / Lowest Target
-9.66%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Beam Therapeutics Inc.

Barclays
RBC Capital Markets
Wedbush
JPMorgan Chase
BofA Securities
Jefferies & Co.
Cantor Fitzgerald
Credit Suisse
Citigroup
Bernstein
Wells Fargo Securities
SVB Securities LLC
BMO Capital
Guggenheim
SVB Leerink
Redburn
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Consensus Beam Therapeutics Inc.